Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Accelerate Diagnostics (AXDX) Stock Price

Media stories about Accelerate Diagnostics (NASDAQ:AXDX) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.2388357579172 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Accelerate Diagnostics (AXDX) opened at $23.30 on Monday. The firm has a market cap of $1,299.36, a P/E ratio of -20.09 and a beta of 2.22. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, February 15th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.05. The firm had revenue of $2.10 million during the quarter. Accelerate Diagnostics had a negative net margin of 1,520.99% and a negative return on equity of 54.66%. analysts predict that Accelerate Diagnostics will post -1.2 earnings per share for the current year.

Several analysts have recently weighed in on the stock. BidaskClub raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Thursday, February 22nd. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. ValuEngine raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BTIG Research cut shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $33.00.

In other Accelerate Diagnostics news, Director Jack W. Schuler bought 20,000 shares of Accelerate Diagnostics stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $24.95 per share, for a total transaction of $499,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler bought 10,000 shares of Accelerate Diagnostics stock in a transaction on Thursday, February 22nd. The shares were acquired at an average price of $25.21 per share, for a total transaction of $252,100.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 45,100 shares of company stock valued at $1,130,850 in the last ninety days. 50.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Accelerate Diagnostics (AXDX) Stock Price” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3302121/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-accelerate-diagnostics-axdx-stock-price.html.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analyzing Liberty Tax Service  & Its Peers
Analyzing Liberty Tax Service & Its Peers
Contrasting Ituran  & Arrow Electronics
Contrasting Ituran & Arrow Electronics
Constellium  vs. Aqua Metals  Head-To-Head Survey
Constellium vs. Aqua Metals Head-To-Head Survey
Brokerages Anticipate Sorrento Therapeutics  Will Announce Earnings of -$0.17 Per Share
Brokerages Anticipate Sorrento Therapeutics Will Announce Earnings of -$0.17 Per Share
Aditus  Price Down 10.6% Over Last 24 Hours
Aditus Price Down 10.6% Over Last 24 Hours
Maecenas Achieves Market Cap of $10.13 Million
Maecenas Achieves Market Cap of $10.13 Million


© 2006-2018 Ticker Report. Google+.